Clinical Trial: A Clinical Trial to Observe the Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Target Population

U.S., July 18 -- ClinicalTrials.gov registry received information related to the study (NCT07071701) titled 'A Clinical Trial to Observe the Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Target Population' on July 08.

Brief Summary: An open clinical trial of a 23-valent pneumococcal polysaccharide vaccine (PPV23) developed by Sinovac Life Science Co., Ltd was conducted to evaluate the safety of Sinovac PPV23 in target population of individuals aged 2 years and above. All participants received 1 dose of PPV23 and self-selected whether to receive 1 dose of influenza vaccine at the same time.

Study Start Date: July 02, 2022

Study Type: OBSERVATIONAL

Condition: Pneumococcal Infectious Disease

Intervention: BIOLOGICAL: 23-val...